Please assess the completion status of the following clinical trial:

Trial Title: CD8 DLI for Patients With Relapse or Residual Disease Following Allogeneic Stem Cell Transplantation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
* Patients of any age who have previously undergone allogeneic hematopoietic transplantation and have evidence of donor cell engraftment (\>20% donor cell within three months of study entry)~* Expected survival \>4 weeks~* CML patients with molecular, cytogenetic or hematologic relapse following allogeneic transplantation~  1. Molecular relapse- patients are eligible if bcr/abl is detectable at any time after day 180 post-allogeneic transplantation or if a negative bcr/abl PCR test was documented post-transplantation and the bcr/abl test is now positive by consecutive PCR determinations at least 4 weeks apart.~ 2. Cytogenetic relapse-patients are eligible if standard cytogenetics demonstrate \>10% t (9,22) positive cells greater than 60 days after myeloablative transplantation or 10% t (9,22) positive cells greater than 100 days after nonmyeloablative transplantation.~* CML patients with accelerated phase or blast crisis following allogeneic transplantation~* Patients with CLL, NHL, MM, or HD who have evidence of disease relapse or persistent disease at 60 days post-allo BMT and/or:~  1. MM- patients with a rising M-protein is detectable at 180 days post-transplant~ 2. NHL - patients with molecular evidence of disease (bcl-2, t (4,11), etc.) at 180 days post transplant~ 3. CLL, NHL or HD - patients with clear cut evidence of tumor growth at any time post-transplant are eligible~* Patients undergoing an HLA -identical or 5/6 antigen match transplant from a related or unrelated donor~* Patient's original donor must be available for lymphocyte donation~* There must be no evidence of active acute or graft-versus-host disease and patients should be off all immunosuppressive agents for, at least, two weeks prior to DLI. Patients on stable dose of methylprednisolone (\<16 mg/d) without evidence of active GVHD are also eligible.~* Patients must have a Zubrod PS\<2 (see appendix 7), Cr\<2.5, bilirubin \<3, and transaminases (SGPT, SGOT) \<4x normal~* Patient must be able to sign informed consent

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CD8 DLI (Type: EXPERIMENTAL): CD8 depleted DLI (Depleted Donor Lymphocyte Infusions)

Based on this trial design, predict the completion outcome and termination type (if applicable).